Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June
Get Alerts GRCL Hot Sheet
Join SI Premium – FREE
SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:
Jefferies Virtual Healthcare ConferenceOne-on-one and small group meetings: June 1-4, 2021Fireside chat: June 4, 2021, 8:00 – 8:25 am ETWebcast link: https://ir.gracellbio.com/news-events/events-and-presentationsThe replay of the fireside chat can be accessed through the “News and Events” section of the Gracell Investor website.For more information, please contact your Jefferies representative.
Citi Pan-Asia Regional Investor ConferenceOne-on-one and small group meetings: June 2-4, 2021For more information, please contact your Citi representative.
About GracellGracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.comFollow @GracellBio on LinkedIn
Media contactMarvin Tang[email protected]
Investor contactGracie Tong[email protected]
Source: Gracell Biotechnologies Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- App Development Costs Drop From $200,000 to Near $50,000 as Chop Dawg Pairs AI-Accelerated Engineering With 18 Years of Discipline
- iAsk AI Launches New Education-Based Hub to Help Students Learn with Artificial Intelligence
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Citi, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share